Guggenheim starts Abivax stock with Buy, cites promising ulcerative colitis drug By Investing.com
On Monday, Guggenheim initiated coverage on Abivax (NASDAQ:ABVX) stock, assigning a Buy rating with a price target of $50.00. The coverage is based on the promising outlook for the company’s lead drug candidate, obefazimod, which is in late-stage development for the treatment of ulcerative colitis (UC). Obefazimod, an oral small molecule, stands out in the … Read more